Yes, according to a post-hoc analysis of data from the controversial COURAGE trial, appearing in the Journal of the American College of Cardiology.
No, according to Dutch researchers whose report on the Secondary Manifestations of Arterial Disease (SMART) study also appears in the journal.
Those findings mimic the state of the field, according to Jacques Genest, MD, of McGill University in Montreal -- it's just not yet clear whether the mass of high-density lipoprotein cholesterol (HDL-C) is even an appropriate biomarker for heart risk.
Role of HDL in Heart Disease Risk
Source: MedPage Today
Image credits: Academic Brooklyn cuny edu
Art and Science of Laboratory Medicine